Visualizing hypothesis tests in survival analysis under anticipated delayed effects
- PMID: 38708672
- DOI: 10.1002/pst.2393
Visualizing hypothesis tests in survival analysis under anticipated delayed effects
Abstract
What can be considered an appropriate statistical method for the primary analysis of a randomized clinical trial (RCT) with a time-to-event endpoint when we anticipate non-proportional hazards owing to a delayed effect? This question has been the subject of much recent debate. The standard approach is a log-rank test and/or a Cox proportional hazards model. Alternative methods have been explored in the statistical literature, such as weighted log-rank tests and tests based on the Restricted Mean Survival Time (RMST). While weighted log-rank tests can achieve high power compared to the standard log-rank test, some choices of weights may lead to type-I error inflation under particular conditions. In addition, they are not linked to a mathematically unambiguous summary measure. Test statistics based on the RMST, on the other hand, allow one to investigate the average difference between two survival curves up to a pre-specified time point -a mathematically unambiguous summary measure. However, by emphasizing differences prior to , such test statistics may not fully capture the benefit of a new treatment in terms of long-term survival. In this article, we introduce a graphical approach for direct comparison of weighted log-rank tests and tests based on the RMST. This new perspective allows a more informed choice of the analysis method, going beyond power and type I error comparison.
Keywords: delayed effects; pseudo‐value; score; survival test; visualization.
© 2024 John Wiley & Sons Ltd.
Similar articles
-
Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.Clin Trials. 2020 Dec;17(6):597-606. doi: 10.1177/1740774520940256. Epub 2020 Sep 15. Clin Trials. 2020. PMID: 32933339
-
A Comparison of Statistical Methods for Time-To-Event Analyses in Randomized Controlled Trials Under Non-Proportional Hazards.Stat Med. 2025 Feb 28;44(5):e70019. doi: 10.1002/sim.70019. Stat Med. 2025. PMID: 39973243 Free PMC article.
-
Comparison between asymptotic and re-randomisation tests under non-proportional hazards in a randomised controlled trial using the minimisation method.BMC Med Res Methodol. 2024 Jul 30;24(1):166. doi: 10.1186/s12874-024-02295-2. BMC Med Res Methodol. 2024. PMID: 39080523 Free PMC article.
-
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.JAMA Oncol. 2022 Sep 1;8(9):1294-1300. doi: 10.1001/jamaoncol.2022.2666. JAMA Oncol. 2022. PMID: 35862037 Free PMC article.
-
Quantifying treatment differences in confirmatory trials under non-proportional hazards.J Appl Stat. 2020 Sep 3;49(2):466-484. doi: 10.1080/02664763.2020.1815673. eCollection 2022. J Appl Stat. 2020. PMID: 35707213 Free PMC article. Review.
References
REFERENCES
-
- Freidlin B, Korn EL. Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis? J Clin Oncol. 2019;37(35):3455.
-
- Freidlin B, Korn EL. Reply to H. Uno et al and B. Huang et al. J Clin Oncol. 2020;38(17):2003‐2004.
-
- Huang B, Wei L‐J, Ludmir EB. Estimating treatment effect as the primary analysis in a comparative study: moving beyond p value. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(17):2001‐2002.
-
- Uno H, Lu T. Is the log‐rank and hazard ratio test/estimation the best approach for primary analysis for all trials? J Clin Oncol Off J Am Soc Clin Oncol. 2020;38(17):2000‐2001.
-
- Lin RS, Lin J, Roychoudhury S, et al. Alternative analysis methods for time to event endpoints under nonproportional hazards: a comparative analysis. Stat Biopharm Res. 2020;12(2):187‐198.
MeSH terms
LinkOut - more resources
Full Text Sources